The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 30, 2023
Filed:
Sep. 10, 2018
Applicant:
Oklahoma Medical Research Foundation, Oklahoma City, OK (US);
Inventor:
Rheal A. Towner, Piedmont, OK (US);
Assignee:
OKLAHOMA MEDICAL RESEARCH FOUNDATION, Oklahoma City, OK (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/205 (2006.01); A61P 35/04 (2006.01); A61P 35/00 (2006.01); A61K 47/68 (2017.01); A61K 31/495 (2006.01); A61K 45/06 (2006.01); A61K 49/10 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 31/205 (2013.01); A61K 31/495 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); A61K 49/10 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); G01N 33/57407 (2013.01); G01N 33/57488 (2013.01);
Abstract
The present disclosure describes the use of 2,4-disulfonyl phenyl tert-butyl nitron (2,4-ds-PBN) in the treatment of temozolomide drug resistant gliomas. The 2,4-ds-PBN may be used combined with other chemo- and radiotherapies and surgery, including temozolomide, to reduce glioma occurrence, recurrence, spread, growth, metastasis, and vascularization, and to inhibit development of temozolomide resistance.